Study on the Effects of Botulinum Toxin in Patients with Jaw Muscle Pain (TMD)

2 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a treatment for a condition known as myogenous temporomandibular disorders (TMD), which is a type of jaw muscle pain. The treatment being tested is botulinum toxin, commonly known for its use in reducing muscle tension. The purpose of the study is to explore how this treatment might change certain biological markers in the jaw muscles of patients with TMD.

Participants in the study will receive an injection of botulinum toxin directly into the jaw muscle. This is done to see if it can help reduce the pain and alter specific biological processes in the muscle. The study will also involve a comparison with a placebo to understand the true effects of the treatment. The treatment period is relatively short, lasting only a few days, and involves a single injection.

The study aims to observe changes in the jaw muscle’s biological markers and pain levels after the treatment. These markers include gene expressions and other cellular changes that might be influenced by the botulinum toxin. The results will help determine if this treatment can effectively reduce jaw muscle pain and provide insights into the underlying mechanisms of TMD.

1 initial assessment

An initial assessment is conducted to confirm eligibility for the trial. This includes verifying a diagnosis of myalgia or myofascial pain with referral, as per the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) axis I.

Eligibility criteria include being female, aged 20 to 45 years, with a characteristic pain intensity greater than 40 out of 100, and experiencing pain upon digital palpation of at least one of the masseter muscles.

2 treatment administration

The treatment involves the administration of botulinum toxin through an intramuscular injection. The specific dosage and frequency are determined by the study protocol and are administered by a healthcare professional.

3 monitoring and follow-up

Regular monitoring is conducted to observe any changes in gene expressions, epigenetic signatures, and cell plasticity in the masseter muscle. This is a primary endpoint of the study.

Secondary endpoints include assessing changes in jaw muscle pain intensity after treatment.

4 completion of trial

The trial is estimated to conclude by March 31, 2025. Upon completion, data collected will be analyzed to determine the effects of the treatment.

Who Can Join the Study?

Must have a diagnosis of myalgia or myofascial pain with referral. This means experiencing muscle pain or pain in the tissues that connect muscles, as identified by specific criteria for jaw-related disorders.
Must be a female aged between 20 and 45 years.
Must have a characteristic pain intensity greater than 40 out of 100. This refers to how strong the pain feels, measured on a scale from 0 to 100.
Must experience pain when pressing on at least one of the masseter muscles. These are the muscles located at the sides of your jaw, used for chewing.

Who Cannot Join the Study?

Patients who are not female cannot participate in the study.
Patients who are under 18 years old cannot participate in the study.
Patients who do not have myogenous temporomandibular disorders (TMDM) cannot participate. This condition involves problems with the muscles around the jaw.
Patients who are considered part of a vulnerable population cannot participate. This means people who might need extra protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Karolinska Institutet	Solna	Sweden

Other Sites

No sites found in this category

Trial status

Country	Status	Recruitment Start
Sweden	Recruiting	09.10.2023

Trial locations

Botulinum Toxin A is a medication used in this clinical trial to study its effects on patients with temporomandibular disorder (TMD) pain. The trial aims to see if this treatment can change gene expressions, epigenetic markers, and cell behavior in the masseter muscle, which is a muscle involved in jaw movement. Botulinum Toxin A is commonly known for its ability to relax muscles and is often used in various medical and cosmetic treatments to reduce muscle tension and pain.

Myogenous Temporomandibular Disorders – This condition involves pain and dysfunction in the muscles that control jaw movement, particularly the masseter muscle. It is characterized by muscle tenderness, limited jaw movement, and pain that can radiate to the face, neck, or shoulders. The disorder often results from muscle overuse, stress, or misalignment of the jaw. Symptoms may include difficulty chewing, jaw locking, and a clicking or popping sound when opening or closing the mouth. Over time, the condition can lead to chronic discomfort and affect daily activities such as eating and speaking.

Trial ID:

2024-514739-12-00

Protocol code:

BTXclintrialv1

NCT ID:

NCT05720065

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effects of Botulinum Toxin in Patients with Jaw Muscle Pain (TMD)

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?